Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Inogen ( (INGN) ).
On May 14, 2025, Inogen, Inc. held its annual meeting of stockholders where they approved the Amended and Restated 2023 Equity Incentive Plan, which increases the number of shares available for issuance by 750,000. This decision, effective immediately upon approval, reflects the company’s strategic move to enhance its equity incentive offerings. Additionally, the meeting saw the election of Class II directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2025, alongside an advisory vote approving executive compensation.
The most recent analyst rating on (INGN) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Inogen stock, see the INGN Stock Forecast page.
Spark’s Take on INGN Stock
According to Spark, TipRanks’ AI Analyst, INGN is a Neutral.
Inogen’s overall stock score reflects its challenging financial performance characterized by declining revenues and persistent losses. While there are some improvements in cash flow and operational efficiencies, negative technical indicators and valuation concerns due to ongoing losses weigh heavily on the score. The earnings call provides some cautious optimism with expected revenue growth and strategic collaborations, but significant challenges remain.
To see Spark’s full report on INGN stock, click here.
More about Inogen
Inogen, Inc. operates in the medical technology industry, primarily focusing on the development and marketing of innovative respiratory products. The company is known for its portable oxygen concentrators, which cater to patients with chronic respiratory conditions, aiming to improve their quality of life.
Average Trading Volume: 348,834
Technical Sentiment Signal: Sell
Current Market Cap: $163.7M
Learn more about INGN stock on TipRanks’ Stock Analysis page.